Carcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas.
|
9731534 |
1998 |
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Normal breast tissues were negative for the L1-MET expression, whereas the triple-negative breast cancer (TNBC) and the high-grade carcinomas were enriched with the L1-MET mRNA (p = 0.005 and p = 0.018, respectively).
|
30144023 |
2018 |
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
c-MET/phospho-MET expression and MET BISH positivity were observed in 22.2%, 5.6%, and 10.9% of NSCLCs, respectively; they were more prevalent in ADCs (27.3%, 6.9%, and 11.5%, respectively) and sarcomatoid carcinomas (20.9%, 9.3%, and 36.6%, respectively) than in SCCs and large cell carcinomas.
|
22198430 |
2012 |
Carcinoma
|
0.400 |
PosttranslationalModification
|
group |
BEFREE |
These results, overall, suggest that the 6.0-kb transcript of the c-met gene might participate in the development and progression of gastric carcinomas.
|
8344755 |
1993 |
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Expression of Met, the Hepatocyte Growth Factor receptor, has been shown to have prognostic value in numerous types of cancer including breast, gastric, cervical and head and neck carcinomas.
|
17260003 |
2007 |
Carcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
In addition to LCs described above, some carcinomas demonstrated low-abundance MET exon 14Δ-specific signal.
|
31472177 |
2019 |
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas.
|
10734314 |
2000 |
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Various solid tumors including lung or gastric carcinomas display aberrant activation of the Met receptor which correlates with aggressive phenotypes and poor prognosis.
|
26238631 |
2015 |
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The present work seeks to assess whether pancreatic carcinomas release exosomes which express c-Met (proto-oncogene mesenchymal-epithelial transition factor) and PD-L1 (programmed cell death 1 ligand 1), and whether the detection of such expression in serum has diagnostic or prognostic meaning for the affected patients.
|
31284422 |
2019 |
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The receptor tyrosine kinase MET is overexpressed in human colorectal adenomas and carcinomas, suggesting an instrumental role for MET signaling in the onset and progression of colorectal cancer.
|
16863504 |
2006 |
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
MET immunostaining was seen in normal urothelium and was recorded in 459 of 560 analyzable urothelial carcinomas (82.0%).
|
24853099 |
2014 |
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
We demonstrate that c-MET receptor protein is present at high levels in primary tumors of human ovaries (clear cell carcinomas).
|
8208549 |
1994 |
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
The EMT and MET have recently been shown to play a key role in the pathogenic processes of sarcomas, which are completely different from those of carcinomas.
|
28829837 |
2017 |
Carcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Overexpression was associated with amplification of the c-met gene in only 10% of carcinomas, but in 8 of 9 metastases examined.
|
9815967 |
1995 |
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
C-Met as a Key Factor Responsible for Sustaining Undifferentiated Phenotype and Therapy Resistance in Renal Carcinomas.
|
30909397 |
2019 |
Carcinoma
|
0.400 |
Biomarker
|
group |
CTD_human |
HGF/c-Met pathway has a prominent role in mediating antiapoptotic signals through AKT in epithelial ovarian carcinoma.
|
20661229 |
2011 |
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In vivo experiments were performed to test the effects of c-MET inhibitor on tumor growth in orthotopic mouse xenografts of OCCC cell line RMG1 and a patient-derived tumor xenograft (PDX) model of OCCC. c-MET expression was significantly greater in OCCCs compared with serous carcinomas and normal ovarian tissues (p < 0.001).
|
27917934 |
2016 |
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
In conclusion, our data suggest that mutation alone plays a minor role in causing aberrancies of the HGF/MET pathway in medulloblastoma in comparison with other malignancies such as breast, hepatocellular, renal, and lung carcinomas.
|
22447520 |
2012 |
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Normal or increased levels of MET mRNA and Met protein were consistently found in fresh samples of carcinomas as well as in epithelial tumor cell lines.
|
1719465 |
1991 |
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The majority of gastric cancers, i.e.76%, express c-MET and in all carcinomas HGF is expressed in either tumor or stromal cells.
|
15026993 |
2004 |
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The results suggest that missense mutations located in the MET proto-oncogene lead to constitutive activation of the MET protein and papillary renal carcinomas.
|
9140397 |
1997 |
Carcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
MET and PD-L1 (SP142) immunohistochemistry was performed in 73 gastric carcinomas with MSI-H.
|
30455128 |
2019 |
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Now we report that the expression of the Met/HGF receptor is increased a hundred fold in 22 out of 41 human carcinomas derived from the thyroid follicular epithelium.
|
1334253 |
1992 |
Carcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In 4 (31%) of the 13 cases enrolled, intratumoral heterogeneity for MET gain was documented in invasive carcinoma components, wherein all the relatively differentiated carcinoma components showed low-level gain of MET and all the corresponding poorly differentiated carcinomas showed high-level gain.
|
21983935 |
2012 |
Carcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
MET mutations were detected in 8.8% (9/102) of triple-negative adenocarcinomas and 20% (9/45) of pleomorphic carcinomas of the lung.
|
28285687 |
2017 |